OxyContin 80mg is the original innovator oral prolonged-release pharmaceutical preparation containing oxycodone hydrochloride<\/b> (developed by Purdue Pharma and marketed in the United Kingdom and internationally by Napp Pharmaceuticals \/ Mundipharma). Chemically designated as $(5R,9R,13S,14S)\\text{-4,5}\\alpha\\text{-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride}$<\/span>, oxycodone is a semi-synthetic phenanthrene alkaloid derived from the opium poppy constituent thebaine. Structurally, it features a morphinan skeleton with a carbon-4 to carbon-5 ether linkage, a methoxy moiety at carbon-3, a tertiary hydroxyl substitution at carbon-14, and an aliphatic ketone functional group at carbon-6. Its empirical molecular formula as the hydrochloride salt is $\\text{C}_{18}\\text{H}_{21}\\text{NO}_4\\cdot\\text{HCl}$<\/span>, yielding an average molecular weight of $351.82\\text{ g\/mol}$<\/span> (unconjugated active base: $315.36\\text{ g\/mol}$<\/span>).<\/p>\n Standard solid oral presentations of OxyContin 80mg in the United Kingdom consist of round, biconvex, green-colored film-coated prolonged-release tablets debossed with “OC” on one face and “80” on the reverse (or “OP” in tamper-resistant, abuse-deterrent polymer formulations deployed in select jurisdictions). The core prolonged-release delivery system utilizes the proprietary Contin<\/b> dual-matrix technology (incorporating hydrophobic and hydrophilic polymers, notably ammonio methacrylate copolymer, hydroxypropyl cellulose, stearyl alcohol, magnesium stearate, and polyethylene glycol) coated with a film layer containing colorants such as indigo carmine (E132), iron oxide yellow (E172), and titanium dioxide (E171). This dual-matrix is engineered to release the substantial $80\\text{ mg}$<\/span> opioid payload in a steady, biphasic profile over a 12-hour period<\/b>.<\/p>\n Within the United Kingdom regulatory framework:<\/p>\n Medicinal Classification:<\/b> Categorized as a Prescription Only Medicine (POM)<\/b> governed by the Human Medicines Regulations 2012.<\/p>\n<\/li>\n Controlled Drug Scheduling:<\/b> Under the Misuse of Drugs Act 1971, oxycodone is scheduled as a Class A controlled substance<\/b>. Under the Misuse of Drugs Regulations 2001, OxyContin 80mg sits within Schedule 2 (CD POM)<\/b>. Prescriptions are subject to strict statutory requirements:<\/p>\n Maximum legal prescription validity of 28 days<\/b> from the date of signature.<\/p>\n<\/li>\n Mandatory declaration of the formulation, strength, dosing instructions, and total quantity written in both words and figures<\/b>.<\/p>\n<\/li>\n Subject to Safe Custody requirements<\/b> (must be stored in a locked Controlled Drugs cupboard conforming to BS 2881 standards within hospital wards and pharmacies) and mandatory logging in the statutory Controlled Drugs Register.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n NHS Formulary Positioning:<\/b> Catalogued in the British National Formulary (BNF) and listed on the NHS Drug Tariff for severe Step 3 opioid analgesia.<\/p>\n<\/li>\n<\/ul>\n Because a single 80mg tablet delivers an equianalgesic dose equivalent to approximately $120\\text{ to }160\\text{ mg}$<\/span> of oral morphine sulphate<\/b>, OxyContin 80mg carries high street-level recognition and commercial diversion value (“Oxy 80s”, “Green OCs”). Bypassing the matrix by crushing, chewing, or aqueous extraction triggers immediate dose-dumping<\/b>, causing rapid systemic absorption capable of inducing fatal respiratory depression, particularly in opioid-naive or partially tolerant individuals. Furthermore, illicit drug markets are extensively contaminated with counterfeit tablets pressed with lethal concentrations of illicit fentanyl or high-potency synthetic nitazene analogues<\/b> (e.g., protonitazene, metonitazene, isotonitazene).<\/p>\n The pharmacodynamic profile of oxycodone is characterized by potent, high-affinity agonism at central and peripheral opioid receptors:<\/p>\n $\\mu$<\/span>-Opioid (MOP) Receptor Agonism:<\/b> Oxycodone functions as a pure, high-efficacy agonist at human $\\mu$<\/span>-opioid receptors distributed across the laminae I and II of the spinal dorsal horn, periaqueductal gray (PAG), thalamus, and cortical sensory processing areas:<\/p>\n Receptor binding activates coupled heterotrimeric inhibitory $G_{\\alpha i\/o}$<\/span> proteins, which inhibit adenylyl cyclase, lowering intracellular cyclic adenosine monophosphate (cAMP).<\/p>\n<\/li>\n Presynaptically, it inhibits voltage-gated N-type calcium ($Ca^{2+}$<\/span>) channels, arresting the vesicular exocytosis of primary nociceptive neurotransmitters (substance P, calcitonin gene-related peptide [CGRP], and L-glutamate).<\/p>\n<\/li>\n Postsynaptically, it stimulates G-protein-coupled inwardly rectifying potassium (GIRK) channels. The resulting potassium ion efflux hyperpolarizes the postsynaptic neuronal membrane, stabilizing resting potentials below the threshold necessary for action potential generation.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Direct Intrinsic Action vs. Active Metabolites:<\/b> Unlike codeine, oxycodone does not require metabolic bioactivation to produce clinical analgesia<\/b>. Parent oxycodone drives approximately $80\\%$<\/span> of its total central analgesic effect. While CYP2D6 converts a fraction into oxymorphone<\/b> (which has an affinity for $\\mu$<\/span>-receptors roughly 10-fold higher than oxycodone), circulating concentrations of oxymorphone remain minimal, meaning variations in CYP2D6 metabolizer status do not significantly alter the primary analgesic response.<\/p>\n<\/li>\n Relative Potency and Morphine Equivalence:<\/b> Oxycodone is a Step 3 opioid:<\/p>\n Oral oxycodone exhibits an equianalgesic potency ratio of approximately $1.5:1\\text{ to }2:1$<\/span> relative to oral morphine<\/b>.<\/p>\n<\/li>\n A single OxyContin 80mg tablet taken every 12 hours delivers analgesic exposure equivalent to $240\\text{ to }320\\text{ mg}$<\/span> of oral morphine sulphate<\/b> over a 24-hour period.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Respiratory and Enteric Depression:<\/b> Agonism within the pontomedullary respiratory pacemakers (pre-B\u00f6tzinger complex) blunts central chemoreceptor responsiveness to arterial carbon dioxide ($\\text{PaCO}_2$<\/span>) and hypoxia, causing dose-dependent bradypnea. In the gastrointestinal tract, stimulation of myenteric $\\mu$<\/span>-receptors arrests propulsive peristalsis and increases circular sphincter tone, universally causing severe constipation.<\/p>\n<\/li>\n<\/ul>\n OxyContin 80mg is indicated strictly for patients who are already established on high-dose opioid therapy<\/b> and require potent Step 3 analgesia under BNF and NICE guidelines:<\/p>\n Severe Cancer-Related Pain:<\/b><\/p>\n Indicated for the control of severe, intractable chronic pain in malignant disease when non-opioids, weak opioids (Step 2), or lower-dose Step 3 opioids fail to provide adequate pain relief.<\/p>\n<\/li>\n Dosed strictly on a 12-hourly schedule<\/b> ($80\\text{ mg}$<\/span> twice daily). Breakthrough pain is managed using immediate-release oral oxycodone (e.g., OxyNorm liquid or capsules), calculated at one-sixth to one-tenth of the total 24-hour baseline dose (e.g., $20\\text{ to }30\\text{ mg}$<\/span> immediate-release PRN for a $160\\text{ mg\/day}$<\/span> total prolonged-release regimen).<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Severe Non-Malignant Chronic Pain (Strictly Specialist-Initiated):<\/b><\/p>\n Short-to-medium-term management of severe chronic pain (e.g., advanced osteoarthritic joint destruction, severe neuropathic conditions, failed back surgery syndrome) refractory to multi-modal non-opioid strategies.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Tolerance Requirements and Opioid-Naive Warning:<\/b><\/p>\n OxyContin 80mg is absolutely contraindicated in opioid-naive patients.<\/b><\/p>\n<\/li>\n Initiation of an 80mg tablet twice daily is reserved exclusively for patients who have demonstrated tolerance by receiving stable, high-dose opioid therapy for at least one to two weeks (e.g., at least $60\\text{ to }80\\text{ mg}$<\/span> of oral morphine daily, $30\\text{ to }40\\text{ mg}$<\/span> of oral oxycodone daily, or an equianalgesic dose of another Step 3 opioid).<\/p>\n<\/li>\n<\/ul>\n<\/li>\n NICE Guidance on Chronic Non-Cancer Pain (NG193):<\/b><\/p>\n NICE explicitly advises against initiating high-potency opioids for chronic primary pain due to lack of evidence for long-term functional recovery, high dependence liabilities, and the risk of opioid-induced hyperalgesia (OIH). Treatment must be accompanied by defined functional goals, scheduled reviews, and an agreed tapering\/exit strategy.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n In non-medical, illicit contexts, OxyContin 80mg is abused for euphoric intoxication, emotional blunting, and somatic sedation. Mechanical tampering (crushing to snort, or dissolving for injection) bypasses the release matrix, creating high risks of fatal overdose.<\/p>\n The pharmacokinetic performance of OxyContin 80mg depends on maintaining matrix integrity to ensure controlled, biphasic 12-hour dissolution:<\/p>\n $N$<\/span>-Demethylation via CYP3A4 (Major Route, $\\sim 80\\%$<\/span>):<\/b> Converts oxycodone into noroxycodone<\/b>. Noroxycodone is a weak $\\mu$<\/span>-opioid agonist with poor blood-brain barrier permeability, contributing negligibly to analgesia.<\/p>\n<\/li>\n $O$<\/span>-Demethylation via CYP2D6 (Minor Route, $\\sim 10\\%$<\/span>):<\/b> Converts oxycodone into oxymorphone<\/b>, a potent $\\mu$<\/span>-opioid agonist. Although oxymorphone has high receptor affinity, its circulating plasma concentrations are low, meaning that genetic CYP2D6 variations do not meaningfully alter the overall analgesic response.<\/p>\n<\/li>\n Phase II Conjugation:<\/b> Unchanged drug and Phase I metabolites undergo glucuronidation via UDP-glucuronosyltransferases into polar glucuronide conjugates for renal excretion.<\/p>\n<\/li>\n Renal Clearance Dynamics:<\/b> Less than $10\\%$<\/span> is excreted unchanged in the urine. In patients with severe renal impairment (eGFR $<30\\text{ mL\/min\/1.73 m}^2$<\/span>), total drug exposure ($AUC$<\/span>) increases by $40\\text{ to }60\\%$<\/span>, requiring conservative dose titration and extended dosing intervals.<\/p>\n<\/li>\n<\/ol>\n Therapeutic administration produces potent analgesia and suppression of pain-associated autonomic distress. However, extensive $\\mu$<\/span>-opioid receptor engagement across multiple organ systems produces a characteristic spectrum of adverse effects:<\/p>\n Gastrointestinal Disturbances (Very Common, $\\ge 1\/10$<\/span>):<\/b><\/p>\n Constipation:<\/b> Occurs in up to $80\\%$<\/span> of treated individuals. Opioid receptor binding in the myenteric plexus inhibits propulsive peristalsis and arrests secretomotor fluid transport. Tolerance does not develop; co-prescribing a prophylactic laxative regimen is clinically mandatory.<\/p>\n<\/li>\n Nausea and vomiting: Triggered by direct stimulation of the chemoreceptor trigger zone (CTZ) in the area postrema.<\/p>\n<\/li>\n Xerostomia (dry mouth), dyspepsia, and biliary spasm (constriction of the Sphincter of Oddi).<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Central Nervous System and Neuropsychiatric Toxicity (Common, $1\/100$<\/span> to $<1\/10$<\/span>):<\/b><\/p>\n Somnolence, daytime sedation, dizziness, headache, and cognitive clouding.<\/p>\n<\/li>\n Euphoria or paradoxical restlessness, dysphoria, and confusion (more frequent in elderly patients).<\/p>\n<\/li>\n Muscle fasciculations, myoclonus, and hyperalgesia (associated with high-dose accumulation).<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Cutaneous Reactions:<\/b><\/p>\n Pruritus, flushing, and diaphoresis. Oxycodone induces significantly less mast-cell degranulation than morphine, but pruritus remains common due to central $\\mu$<\/span>-receptor mechanisms.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Severe, Emergent and Life-Threatening Hazards (Overdose & Dependence):<\/b><\/p>\n Catastrophic Central Respiratory Depression:<\/b> The primary cause of fatal poisoning. Suppression of the medullary pre-B\u00f6tzinger complex produces severe bradypnea ($<8\\text{ breaths\/min}$<\/span>), progressive cyanosis, stupor advancing to coma, hypercapnic acidosis, and fatal cardiac arrest.<\/p>\n<\/li>\n Dose-Dumping Toxicity:<\/b> If an OxyContin 80mg tablet is chewed, crushed, or dissolved, the entire $80\\text{ mg}$<\/span> payload is released immediately ($C_{max}$<\/span> occurs within 30 to 45 minutes rather than 6 to 8 hours), predisposing even opioid-tolerant individuals to acute, potentially fatal respiratory failure.<\/p>\n<\/li>\n Synergistic Depressant Collapse:<\/b> Co-ingestion with alcohol, benzodiazepines, or gabapentinoids (pregabalin, gabapentin)<\/b> dramatically amplifies medullary depression, causing rapid loss of consciousness, airway compromise, and fatal asphyxiation.<\/p>\n<\/li>\n Physical Dependence and Acute Opioid Withdrawal:<\/b> Continuous use beyond 2 to 4 weeks drives neuroadaptation. Abrupt discontinuation precipitates a severe withdrawal syndrome: autonomic hyperactivity (tachycardia, hypertension, diaphoresis), gastrointestinal cramping, diarrhea, piloerection (“cold turkey”), pupil dilation (mydriasis), myalgias, and severe insomnia.<\/p>\n<\/li>\n Counterfeit Nitazene Poisoning:<\/b> Black-market tablets sold as “Oxy 80” frequently contain synthetic nitazene opioids<\/b> (e.g., protonitazene, metonitazene), which exhibit potencies tens to hundreds of times higher than morphine, causing rapid, severe respiratory arrest that requires massive, escalated doses of naloxone.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n Prescribing, titrating, and monitoring OxyContin 80mg mandates strict adherence to safety exclusions, metabolic drug-interaction screening, and Controlled Drugs governance:<\/p>\n Contraindications:<\/b><\/p>\n Opioid-Naive Patients:<\/b> Absolute, Life-Threatening Contraindication.<\/b> Ingestion of $80\\text{ mg}$<\/span> of oxycodone without pre-existing tolerance frequently precipitates fatal respiratory arrest.<\/p>\n<\/li>\n Severe Respiratory Depression:<\/b> Absolute contraindication in acute respiratory failure, severe chronic obstructive pulmonary disease (COPD), respiratory arrest, or acute severe asthma.<\/p>\n<\/li>\n Paralytic Ileus or Obstructive Bowel Disease:<\/b> Absolute contraindication due to the risk of precipitating toxic megacolon or bowel perforation.<\/p>\n<\/li>\n Raised Intracranial Pressure (ICP) and Severe Head Injury:<\/b> Opioid-induced $\\text{CO}_2$<\/span> retention promotes cerebral vasodilation, dangerously spiking intracranial pressure.<\/p>\n<\/li>\n Severe Hepatic Cirrhosis (Child-Pugh Class C):<\/b> Clearance of parent drug is severely blunted, leading to massive, uncontrolled drug accumulation.<\/p>\n<\/li>\n Concurrent Monoamine Oxidase Inhibitors (MAOIs):<\/b> Absolute contraindication during or within 14 days of MAOI therapy.<\/p>\n<\/li>\n Pregnancy and Breastfeeding:<\/b> Avoided during pregnancy unless essential (risks neonatal respiratory depression and neonatal opioid withdrawal syndrome [NOWS]); contraindicated in nursing mothers (oxycodone concentrates in breast milk, causing fatal infant sedation).<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Drug Interactions:<\/b><\/p>\n Potent Cytochrome P450 3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin, Erythromycin, Ritonavir, Grapefruit Juice):<\/i> High-Level Hazard.<\/b> Inhibiting CYP3A4 shuts down the primary clearance pathway of oxycodone, increasing plasma $AUC$<\/span> by $100\\text{ to }200\\%$<\/span><\/b> and doubling its elimination half-life, transforming a standard maintenance dose into a dangerous overdose.<\/p>\n<\/li>\n CYP3A4 Inducers (e.g., Rifampicin, Carbamazepine, Phenytoin, St John\u2019s Wort):<\/i> Accelerates clearance, dropping plasma oxycodone concentrations by up to $50\\text{ to }80\\%$<\/span>, risking acute breakthrough pain crises or opioid withdrawal.<\/p>\n<\/li>\n\n
\n
2. Mechanism of Action and Pharmacodynamics<\/h2>\n
\n
\n
\n
3. Approved UK Clinical Indications and Therapeutic Scope<\/h2>\n
\n
\n
\n
\n
\n
4. Pharmacokinetic Profile and Metabolic Fate<\/h2>\n
\n\n
\n Pharmacokinetic Parameter<\/strong><\/td>\n Value \/ Metric<\/strong><\/td>\n Clinical Interpretation<\/strong><\/td>\n<\/tr>\n<\/thead>\n\n \n Oral Bioavailability<\/b><\/span><\/td>\n $60\\text{ to }87\\%$<\/span><\/b><\/span><\/td>\n High and consistent compared to oral morphine ($20\\text{\u2013}40\\%$<\/span>).<\/span><\/td>\n<\/tr>\n \n Release Pattern \/ $T_{max}$<\/span><\/b><\/span><\/td>\n Biphasic: Initial peak at $1\\text{ to }3\\text{ hours}$<\/span><\/b>, broad second peak at $6\\text{ to }8\\text{ hours}$<\/span><\/b><\/span><\/td>\n Sustains constant therapeutic plasma concentrations over 12 hours.<\/span><\/td>\n<\/tr>\n \n Volume of Distribution ($V_{ss}$<\/span>)<\/b><\/span><\/td>\n $2.6\\text{ to }3.2\\text{ L\/kg}$<\/span><\/b><\/span><\/td>\n Extensive extravascular and central nervous system tissue distribution.<\/span><\/td>\n<\/tr>\n \n Plasma Protein Binding<\/b><\/span><\/td>\n $\\sim 45\\%$<\/span> (Moderate)<\/span><\/td>\n Bound primarily to human serum albumin; low displacement interaction risk.<\/span><\/td>\n<\/tr>\n \n Primary Hepatic Enzymes<\/b><\/span><\/td>\n CYP3A4<\/b> ($\\sim 80\\%$<\/span>), CYP2D6<\/b> ($\\sim 10\\%$<\/span>)<\/span><\/td>\n High susceptibility to systemic CYP3A4 inhibitors and inducers.<\/span><\/td>\n<\/tr>\n \n Active Metabolites<\/b><\/span><\/td>\n Oxymorphone<\/b> (potent, low concentration), Noroxycodone (weak)<\/span><\/td>\n Parent drug drives the overwhelming majority of clinical efficacy.<\/span><\/td>\n<\/tr>\n \n Elimination Route<\/b><\/span><\/td>\n Renal ($80\\%$<\/span>, unconjugated drug and metabolites)<\/span><\/td>\n Elimination is prolonged in moderate-to-severe renal failure.<\/span><\/td>\n<\/tr>\n \n Elimination Half-Life ($t_{1\/2}$<\/span>)<\/b><\/span><\/td>\n Apparent $t_{1\/2} \\approx \\mathbf{4.5\\text{ to }6.5\\text{ hours}}$<\/span><\/span><\/td>\n Prolonged by ongoing release from the polymer matrix (flip-flop kinetics).<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n Biotransformation Pathways<\/h3>\n
\n
5. Physiological Effects and Adverse Event Spectrum<\/h2>\n
\n
\n
\n
\n
\n
6. Contraindications, Drug Interactions, and Clinical Precautions<\/h2>\n
\n
\n
\n